西地尼布在卵巢癌治疗中的研究进展

Advances in Study of Cediranib in Ovarian Cancer Treatment

中国卵巢癌的发病率仅次于宫颈癌和子宫内膜癌,但由于卵巢癌早期症状隐匿,发现时多处于疾病晚期,常合并腹腔种植。卵巢癌的死亡率居女性生殖器恶性肿瘤的首位。肿瘤细胞减灭术结合铂类/紫杉醇联合化疗可暂时缓解晚期卵巢癌患者的病情,但复发率高、预后差,多数患者在反复间断化疗后出现耐药。靶向药物西地尼布是目前最有前景的口服抗血管生成酪氨酸激酶抑制剂,可为卵巢癌的治疗提供新思路。

The incidence of ovarian cancer in Chinese women is second only to cervical cancer and endometrial cancer,but the mortality rate is the highest among female genital malignancies.The high mortality of ovarian cancer is mainly due to the insidious early symptoms of the disease,and the patients diagnosed are often at advanced stage combined with intraperi-toneal implantation.For patients with advanced ovarian cancer,tumor cell reduction plus platinum/paclitaxel combined chemotherapy can temporarily alleviate the disease.However,the recurrence rate is high and the prognosis is poor,and drug resistance will occur in most patients after repeated intermittent chemotherapy.The targeted drug cediranib is the most promising oral anti-angiogenic tyrosine kinase inhibitor under study,which opens up a new perspective for the treatment of the patients.